Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Comments are welcome to point out any issues. This article is only an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if involved). This article does not constitute any investment advice.
Today,AusperBio Announces Completion of $73 Million Series B Financing. The financing will mainlyFor Advancing the Core Small Nucleic Acid Innovative Drug AHB-137 in Clinical Trials in China and Internationally`, as well as the preparations for early commercialization. In addition, the funds will also support the expansion of the company's new R&D pipeline and the continuous development and construction of the team.`This round of financing was led by Hankang Capital, with follow-up investments from Sherpa Healthcare Partners, CDH VGC, and a globally renowned industry investment institution. Meanwhile, previous investors Qiming Venture Partners, InnoPinnacle Fund, and YuanBio Venture Capital also increased their investments.
AusperBio is an innovative biopharmaceutical company with a global presence and in the clinical stage, committed to transforming hepatitis B curative therapies and leading innovations in oligonucleotide technology. Leveraging its proprietary Med-Oligo™ ASO platform and highly efficient targeted delivery technology, the company focuses on revolutionary ASO therapies applied in areas such as viral infections, metabolic diseases, genetic disorders, and immune-related conditions.AHB-137 is an innovative unconjugated antisense oligonucleotide (ASO) drug that specifically targets all HBV mRNAs for the treatment of chronic hepatitis B.AHB-137 is currently conducting a Phase I international multicenter clinical trial and a Phase II clinical trial in China.On July 11 this year, due to its significant clinical advantages compared with existing treatments, AHB-137 was included as a breakthrough therapy drug by the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) of China. In November, AusperBio presented preliminary results from the Phase IIa study of AHB-137 for the treatment of chronic hepatitis B at the AASLD2024 conference. The results showed:All subjects have completed at least 12 weeks of AHB-137 treatment. Serum HBsAg levels decreased rapidly after drug administration.By Week 12, 62% of subjects (20/32) in the 300 mg treatment group and 43% of subjects (10/23) in the 225 mg treatment group achieved HBsAg seroclearance, primarily during the initial 8 weeks of treatment (44% and 30%, respectively).About Chronic Hepatitis BAccording to WHO estimates, 290 million people were infected with chronic hepatitis B in 2022, with an estimated 1.2 million new infections and 1.1 million deaths annually. The clearance of hepatitis B surface antigen (HBsAg) is considered the optimal treatment endpoint, also known as "functional cure." However, current treatments rarely achieve this goal, thus there is an urgent need for innovative therapies that can achieve functional cure.References:
Company Announcement
Public Information
